Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:4434 |
| Name | small intestine neuroendocrine neoplasm |
| Definition | |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm gastrointestinal system benign neoplasm intestinal benign neoplasm small intestine benign neoplasm small intestine neuroendocrine neoplasm |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
| NCT04954820 | Phase II | Lutetium Lu 177 dotatate | Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor (ReLUTH) | Recruiting | FRA | 0 |
| NCT05773274 | Phase II | Everolimus Lutetium Lu 177 dotatate | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial | Recruiting | USA | CAN | 0 |
| NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |
| NCT06878664 | Phase III | Lutetium Lu 177 dotatate + Octreotide acetate Lanreotide acetate + Lutetium Lu 177 dotatate | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (RIALTO) | Recruiting | FRA | ESP | 0 |